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Epidermal growth factor receptor (EGFR)‐activating mutations confer sensitivity to
tyrosine kinase inhibitor (TKI) treatment for non‐small‐cell lung cancer (NSCLC).
ASP8273 is a highly specific, irreversible, once‐daily, oral, EGFR TKI that inhibits
both activating and resistance mutations. This ASP8273 dose‐escalation/dose‐expan-
sion study (NCT02192697) was undertaken in two phases. In phase I, Japanese
patients (aged ≥20 years) with NSCLC previously treated with ≥1 EGFR TKI
received escalating ASP8273 doses (25‐600 mg) to assess safety/tolerability and to
determine the maximum tolerated dose (MTD) and/or the recommended phase II
dose (RP2D) by the Bayesian Continual Reassessment Method. In phase II, adult
patients with T790M‐positive NSCLC in Japan, Korea, and Taiwan received
ASP8273 at RP2D to further assess safety/tolerability and determine antitumor
activity, which was evaluated according to Simon's two‐stage design (threshold
response = 30%, expected response = 50%, α = 0.05, β = 0.1). Overall, 121 (n = 45
[33W/12M] phase I, n = 76 [48W/28M]) phase 2) patients received ≥1 dose of
ASP8273. In phase I, RP2D and MTD were established as 300 and 400 mg, respec-
tively. As 27 of the 63 patients treated with ASP8273 300 mg achieved a clinical
response, ASP8273 was determined to have antitumor activity. The overall response
rate at week 24 in all patients was 42% (n = 32/76; 95% confidence interval, 30.9‐54.0).
Median duration of progression‐free survival was 8.1 months (95% confidence interval,
5.6, upper bound not reached). Themost commonly reported treatment‐related adverse
event in phase II was diarrhea (57%, n = 43/76). ASP8273 300 mg was generally well
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tolerated and showed antitumor activity in Asian patients with both EGFR‐activating
and T790Mmutations.
K E YWORD S
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1 | INTRODUCTION
The presence of EGFR‐activating mutations in patients with NSCLC
can result in increased malignant cell survival, proliferation, invasion,
metastatic spread, and tumor angiogenesis.1,2 These mutations are
estimated to be present in approximately 50% of patients with
NSCLC in East Asian countries.3 Exon 19 deletions and exon 21
L858R substitutions are the most common EGFR mutations.1,4 These
mutations confer sensitivity to TKIs and account for approximately
90% of EGFR mutations in patients with NSCLC.5
Patients with NSCLC with EGFR‐activating mutations have experi-
enced antitumor activity and prolonged PFS following treatment with
the reversible EGFR TKIs such as gefitinib and erlotinib.6,7 However,
this clinical efficacy is often limited by an acquired drug resistance,
most commonly caused by a point mutation (T790M) in the gene
encoding EGFR. Approximately 50%‐60% of patients treated with TKIs
develop T790M‐mediated resistance, suggesting that, along with acti-
vating mutations, the T790M mutation is an important factor in deter-
mining the appropriate treatment strategy in these patients.8,9
ASP8273 is an oral, irreversible EGFR TKI that inhibits the kinase
activity of EGFR containing the ex19del‐ or L858R‐activating muta-
tion and the T790M resistance mutation with higher potency than
WT EGFR. Based on preclinical activity, ASP8273 was evaluated in a
phase I/II study in patients with EGFR‐mutant lung cancer in Japan.
The primary objectives for phase I of this study were to assess
safety/tolerability of ASP8273 as well as to determine the MTD and/or
the RP2D based on the DLT profile. Secondary objectives were to
determine the pharmacokinetics and antitumor activity of ASP8273. In
phase II, the primary objective was to determine the antitumor activity
of ASP8273; secondary objectives were to determine the safety and
pharmacokinetics of ASP8273. Here, we report the results from study
initiation date, January 2014, until the cut‐off date, 15 January 2016.
2 | MATERIALS AND METHODS
2.1 | Study design and treatment
This dose‐escalation/dose‐expansion study (NCT02192697) was
undertaken in two phases. Phase I, consisting of a dose‐escalation
cohort, an additional T790M cohort, and a re‐enrollment cohort, was
undertaken in four centers in Japan and phase II was held in 15 centers
across Japan, Taiwan, and Korea (Figure 1). Eligible patients with
NSCLC were aged ≥20 years, had given written informed consent, had
an ECOG performance status ≤1, had a histologically or cytologically
confirmed diagnosis of NSCLC, were confirmed to have the ex19del,
L858R, G719X, or L861Q mutation among the EGFR‐activating muta-
tions, and had a life expectancy ≥12 weeks based on investigator's
judgment. Eligible patients also met all of the following requirements
for laboratory tests within 7 days before enrollment: neutrophil count
≥1500/mm3, platelet count ≥75 000/mm3, hemoglobin ≥9 g/dL, serum
creatinine <1.5 mg/dL, total bilirubin <1.5× the upper limit of normal
(this did not apply to patients with Gilbert's syndrome), and AST and
ALT <2.5× the upper limit of normal.
For enrollment in phase I, patients were not expected by the inves-
tigator to show a therapeutic response to existing treatments. Patients
were enrolled irrespective of T790M mutation status. For phase II,
patients had confirmed PD after previous treatment with EGFR TKIs,
and had expression of the EGFR T790M mutation centrally confirmed
by a tumor biopsy of the primary or metastatic lesions or by a tumor tis-
sue sample that had been collected and archived after confirmation of
PD. Patients were excluded from participation if any of the following
applied at the time of enrollment: (i) persistent clinical evidence of pre-
vious antitumor treatment‐related toxicity grade ≥2 (using the NCI‐
CTCAE version 4.0), except alopecia and skin toxicities considered irrel-
evant by the investigator during study enrollment; (ii) history of or con-
current interstitial lung disease; (iii) received treatment with gefitinib
within 8 days or erlotinib within 5 days before the start of study treat-
ment; (iv) received previous treatment (except reversible EGFR TKIs)
intended to have antitumor effects or treatment with another investi-
gational drug or an investigational device within 14 days prior to the
start of study treatment; and (v) received treatment with EGFR TKIs
(eg, rociletinib, osimertinib) that can inhibit EGFR with the T790M
mutation (this did not apply to the re‐enrollment cohort). The dose‐
escalation and additional EGFR‐T790M parts consisted of two periods:
a single‐dose period (cycle 0 lasting 2 days) and a multiple‐dose period
(from cycle 1 onwards, each cycle lasting 21 days).
During phase I, patients received escalating ASP8273 doses (25‐
600 mg). At least three patients were enrolled at each dose level,
depending on the occurrence of DLTs in cycles 0 and 1. Patients
enrolled at one dose level were not enrolled at other dose levels.
ASP8273 was given at an initial dose of 25 mg, and then escalated to
higher dose levels set at 50, 100, 200, 400, and 600 mg. Among these
dose levels, the next recommended dose level was selected according
to the posterior mean of DLT rate estimated by the Bayesian continual
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reassessment method. Dose‐limiting toxicities were defined as the fol-
lowing study drug‐related AEs: (i) grade 4 neutropenia; (ii) grade ≥3 feb-
rile neutropenia; (iii) grade 4 thrombocytopenia or grade 3
thrombocytopenia with bleeding that requires platelet transfusion; (iv)
grade ≥3 nonhematologic toxicity; (v) transient electrolyte imbalance
that is not accompanied by any clinical signs or symptoms and that does
not require continuous therapeutic intervention; (vi) diarrhea, nausea,
and vomiting that can be improved to grade ≤2 with appropriate treat-
ment; (vii) grade 3 AST and ALT levels that improve to grade ≤2 within
7 days after onset; and (viii) any toxicity resulting in a delay (≥11 days)
of study treatment with ASP8273. The final judgment on DLTs was
made by the investigator and the sponsor, and the severity of each of
the AEs was assessed according to NCI‐CTCAE version 4.0. The next
dose level was determined after the end of cycle 1 assessments in all
patients enrolled in the last dose‐escalation cohort. The decision to
escalate to the next dose was based on safety and efficacy data and
was determined by the investigators and study sponsor during a dose‐
escalation meeting. In the re‐enrollment portion of the study, a patient
who discontinued the study due to PD in the 25 mg cohort during
phase I (dose‐escalation) could be re‐enrolled and treated with
ASP8273 as multiple oral doses, once‐daily in each 21‐day cycle, at the
RP2D of 300 mg until discontinuation. In this study, DLTs were
assessed only during cycles 0 and 1 of the dose‐escalation and addi-
tional EGFR T790M parts of phase I. TheMTDwas defined as the high-
est dose of ASP8273 at which the incidence of DLTs was estimated to
be the closest to 33%.
The study was designed by the study sponsor in collaboration
with the investigators and was carried out in accordance with the
protocol, the International Council for Harmonisation of Technical
Requirements for Pharmaceuticals for Human Use guidelines, appli-
cable regulations and guidelines governing clinical study conduct,
and the ethical principles of the Declaration of Helsinki.
2.2 | Study end‐points and assessments
A primary end‐point of phase I was to determine the safety and tolera-
bility of ASP8273 based on DLTs (excluding the re‐enrollment part),
AEs, clinical laboratory tests, bone turnover markers, vital signs,
percutaneous oxygen saturation, body weight, 12‐lead electrocardio-
grams, ophthalmologic examination, chest X‐ray examination, chest
computed tomography examination, and ECOG performance status.
Adverse events were graded using the NCI‐CTCAE version 4.0. Labo-
ratory safety assessments included monitoring hematology and blood
chemistry. The other primary end‐point for phase I was to determine
the MTD and/or RP2D of ASP8273 based on the DLT profiles.
Secondary objectives of phase I during dose‐escalation and addi-
tional T790M cohorts were to determine the antitumor activity of
ASP8273. Tumor lesions were assessed with an imaging technique
such as radiography, chest computed tomography, or MRI on days 1
(predose) and 21 for each treatment cycle. Antitumor activity was
determined according to RECIST version 1.1 and measured by best
overall response, ORR (CR + PR), DCR (CR + PR + SD), PFS, and dura-
tion of response.
The primary objective in phase II was to determine the antitumor
activity of ASP8273 as measured by best overall response at week 24
and cut‐off date, ORR (based on central review at week 24 and cut‐off
date), as well as DCR at week 24 and cut‐off date; safety and tolerabil-
ity of ASP8273 was a secondary end‐point of phase II. ASP8273 sin-
gle‐ and repeat‐dose pharmacokinetics profiles, including dose
proportionality (phase I) and ethnic differences (phase II) were sec-
ondary end‐points in both phases.
Pharmacokinetic parameters of ASP8273 were evaluated by
plasma sampling in both phase I and phase II. During phase I, blood
was drawn on cycle 0 day 1 (predose) and 0.5, 1, 2, 4, 6, 8, 10, 24,
34, and 48 hours postdose before dosing on cycle 1 day 1 and days
8, 15, 18, and 21. Phase II blood sampling was carried out cycle 1
day 1 (predose) and 0.5, 1, 2, 4, 6, 8, and 24 hours postdose; also
before dosing on cycle 1 day 2, and days 8, 15, and 21. An EGFR‐
mutation test using histological or cytological samples, optional in
phase I but required in phase II, were analyzed at a central EGFR
gene testing laboratory using the therascreen EGFR RGQ PCR kit
(Qiagen, Hilden, Germany). For this purpose, either tumor biopsy
samples of the primary or metastatic lesions or an archived tumor
tissue sample were used. Samples for EGFR‐activating mutations
(ex19del, L858R, L861Q, and G719X) and for the EGFR T790M
mutation were also analyzed.
F IGURE 1 Study design involving
patients with non‐small‐cell lung cancer
(NSCLC) with epidermal growth factor
receptor‐activating and T790M mutations
treated with ASP8273. Phase I, dose
escalation; phase II, dose expansion
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2.3 | Statistical analysis
All patients who received at least one dose of ASP8273, who had
acceptable images for baseline tumor assessment, and who were
evaluated for at least one efficacy end‐point after start of treatment
were included in the full analysis set. Patients who received at least
one dose of ASP8273 were included in the safety analysis set.
For phase I, the ORR, defined as the proportion of patients with
best overall response over the entire exposure period was rated as CR
or PR, was calculated by dose in each part and its 95% CI (Clopper‐Pear-
son) is presented. For phase II, the ORR at week 24 (by central and local
review) and for the entire treatment period (by central review only)
were calculated. The antitumor activity of ASP8273 based on RECIST
version 1.1 in phase II was evaluated according to Simon's two‐stage
design (uninteresting response = 30%, desired response = 50%,
α = 0.05, β = 0.1). If 9 or more of the 24 ASP8273‐treated patients
achieved response in the first stage, then 39 additional patients would
be enrolled. If ≥25 of 63 total patients achieved response, ASP8273
would be considered to have antitumor effects based on the observed
response rate equal to or more than the threshold response rate of
30%. Adverse events were coded according to the Medical Dictionary
for Regulatory Activities version 16.1. It was used to summarize AEs by
System Organ Class and preferred term for both study phases. The
number and percentage of patients experiencing DLTs were summa-
rized by study drug dose.
3 | RESULTS
3.1 | Disposition, demographics, and disease
characteristics of the overall study
In phase I of this study, 49 patients provided informed consent to
participate in the clinical study (Figure 2). A total of 47 patients were
enrolled and received the study drug; 45 patients were included in
safety and efficacy analyses. The majority of patients were women
(n = 33; 73%), all were clinical stage IV, and the majority of patients
never smoked (n = 33; 73%). The EGFR ex19del (n = 30; 67%) and
L858R (n = 14; 31%) activating mutations were common in this pop-
ulation; 23 patients (51%) harbored a T790M resistance mutation,
with the T790M mutation status unknown for 16 patients (Table 1).
The median duration of exposure was 170 days overall and the
mean compliance rate was 92%.
Of the 147 patients who provided informed consent to partici-
pate in phase II of this study (carried out in Japan, Korea, and Tai-
wan), 76 were enrolled and received the study drug; all 76 patients
were included in the safety analysis set and full analysis set. Similar
to phase I, more women (n = 48; 63%) than men (n = 28; 37%) were
enrolled, the majority of patients never smoked (n = 51; 67%), and
were clinical stage IV (n = 68; 90%). All patients (n = 76) had an
EGFR T790M resistance mutation, 52 (68%) had an ex19del‐activat-
ing mutation, and 22 (29%) had an L858R EGFR-activating mutation.
For this cohort, the median duration of study drug exposure was
196 days and the mean compliance rate was 94%.
3.2 | Phase I
3.2.1 | Safety and tolerability of ASP8273 (25‐
600 mg)
Across the wide ASP8273 dose‐escalation range (25‐600 mg), TEAEs
occurring in ≥20% of all patients were diarrhea (76%; n = 34), nausea
(53%; n = 24), vomiting (49%; n = 22), increased ALT (47%; n = 21),
decreased appetite and peripheral sensory neuropathy (38%; n = 17
each), increased AST (36%; n = 16), increased blood creatinine and
constipation (33%; n = 15 each), hyponatremia and platelet count
decreased (31%; n = 14 each), hypoalbuminemia (22%; n = 10), and
F IGURE 2 Study disposition involving
patients with non‐small‐cell lung cancer
(NSCLC) with epidermal growth factor
receptor‐activating and T790M mutations
treated with ASP8273. Phase I, dose
escalation; phase II, dose expansion
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anemia, dry skin, dysgeusia, and malaise (20%; n = 9 each). No deaths
were reported during phase I. Serious TEAEs reported in phase I were
dehydration, hyponatremia, and diarrhea (4%; n = 2 each).
As detailed in Table 2, diarrhea (76%; n = 34), vomiting and
increased ALT (44%; n = 20), nausea (42%; n = 19), peripheral sen-
sory neuropathy (36%; n = 16), increased AST, increased blood crea-
tinine, and decreased platelet count (31%; n = 14 each) were the
most commonly reported TRAEs in phase I. Most of the TRAEs were
grade ≤2 in severity; the grade ≥3 TRAEs occurring in ≥2 patients
were hyponatremia (20%; n = 9), diarrhea (18%; n = 8), increased
AST and anemia (7%; n = 3 each), and colitis, hypoalbuminemia, nau-
sea, and peripheral sensory neuropathy (4%; n = 2 each).
Dose‐limiting toxicities were experienced by 9 patients during
the study; specifically, 5 patients in the 400 mg dose group and 4
TABLE 1 Demographic and baseline disease characteristics of patients with non‐small‐cell lung cancer with epidermal growth factor



















69 (43‐74) 65 (47‐74) 60 (28‐74) 67 (42‐78) 66 (60‐78) 65 (28‐78) 63 (39‐83)
Sex, n (%)
Male 5 (45) 1 (10) 3 (30) 2 (20) 1 (25) 12 (27) 28 (37)
Female 6 (55) 9 (90) 7 (70) 8 (80) 3 (75) 33 (73) 48 (63)
ECOG performance status, n (%)
0 2 (18) 5 (50) 3 (30) 3 (30) 3 (75) 16 (36) 20 (26)
1 9 (82) 5 (50) 7 (70) 7 (70) 1 (25) 29 (64) 56 (74)
Number of prior EGFR TKI treatments, n (%)
1 4 (36) 6 (60) 6 (60) 6 (60) 3 (75) 25 (56) 45 (59)
2 7 (64) 4 (40) 1 (10) 4 (40) 1 (25) 17 (38) 21 (28)
3 0 (0) 0 (0) 3 (30) 0 (0) 0 (0) 3 (7) 10 (13)
Patients with EGFR‐activating mutation, n (%)
Exon 19 Del 6 (55) 6 (60) 8 (80) 7 (70) 3 (75) 30 (67) 52 (68)
L858R 5 (45) 3 (30) 2 (20) 3 (30) 1 (25) 14 (31) 22 (29)
T790M mutation status, n (%)
Positive 3 (27) 8 (80) 5 (50) 7 (70) 0 (0) 23 (51) 76 (100)
Negative 0 (0) 2 (20) 3 (30) 0 (0) 1 (25) 6 (13) 0 (0)
Unknown 8 (73) 0 (0) 2 (20) 3 (30) 3 (75) 16 (36) 0 (0)
Minor mutations, n (%)
L861Q 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 2 (3)
G719X 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 1 (1)
Other 0 (0) 1 (10) 0 (0) 1 (10) 1 (25) 3 (7) 6 (8)
Tobacco history, n (%)
Never smoked 6 (55) 8 (80) 8 (80) 8 (80) 3 (75) 33 (73) 51 (67)
Current smoker 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0)
Former smoker 5 (45) 2 (20) 2 (20) 2 (20) 1 (25) 12 (27) 25 (33)
Clinical stage, n (%)
0 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0)
IA 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0)
IB 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0)
IIA 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 3 (4)
IIB 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 1 (1)
IIIA 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 2 (3)
IIIB 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 2 (3)
IV 11 (100) 10 (100) 10 (100) 10 (100) 4 (100) 45 (100) 68 (90)
TKI, tyrosine kinase inhibitor.
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patients in the 600 mg dose group. All DLTs were of grade ≥3 non-
hematologic toxicity, and the most common DLTs were diarrhea
(7%; n = 3), followed by colitis, nausea (4%; n = 2 each), and malaise,
biliary tract infection, and hyponatremia (2%; n = 1 each). Based on
the Bayesian continual reassessment method, the 400 mg dose was
recommended as the MTD.
3.2.2 | Pharmacokinetics of ASP8273
ASP8273 showed linear pharmacokinetics and dose proportionality
over the dose range of 100 to 400 mg in phase I (Figure 3; Tables
S1-S5). Steady‐state ASP8273 was achieved by cycle 1 day 8 after
once‐daily dosing. After 21 days of daily dosing, approximately 30%‐
60% accumulation AUC was observed. During phase II, approxi-
mately 20% accumulation AUC was observed after 21 days of daily
dosing. The exposures of ASP8273 were comparable among the
group (Korean, Taiwanese, and Japanese).
3.2.3 | Phase I antitumor activity
Across the dose range (25‐600 mg), the ORR was 49% (95% CI, 33.7,
64.2). Although no patient achieved a CR, 22 patients achieved PR;
additionally, 18 patients achieved SD and five had PD (Table 3). Dis-
ease control rate, defined as CR + PR + SD, was high (89%; n = 40)
and the median duration of PFS was 5.6 months (95% CI: 3.6, 11.1).
The duration of response, as assessed by local review, was 8.4 months
(95% CI, 4.2, 11.0) in the total population. The proportion of patients with
maximum shrinkage from baseline in the target lesion ≥30% was 55%
(n = 24/44) (Figure 4). Most patients in all dose groups had shrinkage in
the target lesion with no clear correlation between degree of percent
change from baseline in the target lesion and the dose level of ASP8273.
When antitumor activity was assessed by T790M status, ORRs
and DCRs with ASP8273 (25‐600 mg) were higher in patients with a
known T790M mutation than patients with no T790M mutation
(Table 4). Patients with unknown T790M status had response rates
that were similar to patients with known T790M. However, due to
the small number of patients in these subgroups, these data should
be interpreted with caution.
Based on these efficacy data and a comprehensive evaluation of
safety, including the DLT profile and pharmacokinetic data, the
RP2D was determined to be 300 mg.
3.3 | Phase II
3.3.1 | Antitumor activity
As 27 of the 63 patients treated with ASP8273 300 mg, in the first
and second stages of phase II combined, achieved a clinical response
(based on independent central review), ASP8273 was determined to
have shown antitumor activity (ORR 43%; 95% CI, 30.5, 56.0).
TABLE 2 Incidence of overall treatment‐related adverse events (TRAEs) and grade ≥3 TRAEs occurring in ≥20% of patients with non‐small‐
cell lung cancer treated with ASP8273 (phase I)
TRAE, n (%)
25‐100 mg














Diarrhea 5 (45) 0 (0) 8 (80) 0 (0) 7 (70) 1 (10) 10 (100) 5 (50) 4 (100) 2 (50) 34 (76) 8 (18)
Nausea 3 (27) 0 (0) 3 (30) 0 (0) 4 (40) 0 (0) 7 (70) 1 (10) 2 (50) 1 (25) 19 (42) 2 (4)
Vomiting 2 (18) 0 (0) 3 (30) 0 (0) 6 (60) 0 (0) 6 (60) 0 (0) 3 (75) 0 (0) 20 (44) 0 (0)
ALT increased 1 (9) 0 (0) 5 (50) 0 (0) 5 (50) 2 (20) 7 (70) 1 (10) 2 (50) 0 (0) 20 (44) 3 (7)
Decreased appetite 2 (18) 0 (0) 4 (40) 1 (10) 2 (20) 0 (0) 2 (20) 0 (0) 2 (50) 0 (0) 12 (27) 1 (2)
Peripheral sensory
neuropathy
4 (36) 1 (9) 3 (30) 0 (0) 2 (20) 0 (0) 4 (40) 1 (10) 3 (75) 0 (0) 16 (36) 2 (4)
AST increased 0 (0) 0 (0) 4 (40) 0 (0) 4 (40) 0 (0) 4 (40) 0 (0) 2 (50) 0 (0) 14 (31) 0 (0)
Blood creatinine
increased
2 (18) 0 (0) 2 (20) 0 (0) 2 (20) 0 (0) 5 (50) 0 (0) 3 (75) 0 (0) 14 (31) 0 (0)
Constipation 3 (27) 0 (0) 3 (30) 0 (0) 0 (0) 0 (0) 3 (30) 0 (0) 1 (25) 0 (0) 10 (22) 0 (0)
Hyponatremia 0 0 (0) 4 (40) 3 (30) 0 (0) 0 (0) 5 (50) 5 (50) 2 (50) 1 (25) 11 (24) 9 (20)
Platelet count decreased 3 (27) 0 (0) 2 (20) 0 (0) 3 (30) 0 (0) 3 (30) 0 (0) 3 (75) 0 (0) 14 (31) 0 (0)
Dysgeusia 1 (9) 0 (0) 3 (30) 0 (0) 1 (10) 0 (0) 1 (10) 0 (0) 3 (75) 0 (0) 9 (20) 0 (0)
Malaise 2 (18) 0 (0) 1 (10) 0 (0) 0 (0) 0 (0) 5 (50) 1 (10) 1 (25) 0 (0) 9 (20) 1 (2)
TRAEs of special interest
Rash 1 (9) 0 (0) 0 (0) 0 (0) 2 (20) 0 (0) 1 (10) 0 (0) 1 (25) 0 (0) 5 (11) 0 (0)
QTc prolongation 1 (9) 0 (0) 0 (0) 0 (0) 2 (20) 0 (0) 1 (10) 0 (0) 0 (0) 0 (0) 4 (9) 0 (0)
Interstitial lung disease 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 1 (25) 0 (0) 1 (2) 0 (0)
ALT, alanine transaminase; AST, aspartate aminotransferase.
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The ORR at week 24, which was assessed at an independent
central site, for the phase II population (N = 76) treated with
ASP8273 300 mg, was 42% (n = 32; 95% CI, 30.9, 54.0). A total of
32 patients achieved PR, 29 achieved SD, and 8 had PD (Table 5).
Disease control rate was 80% and the median duration of PFS by
central review was 8.1 months (95% CI, 5.6, upper bound not
reached). The proportion of evaluable patients with maximum shrink-
age from baseline in the target lesion ≥30%, which was centrally
assessed, was 67% (n = 46). As seen in Figure 5, almost all patients
had shrinkage in target lesions. Based on central‐tissue testing, the
ORR and median duration of PFS were also estimated by the pres-
ence or absence of EGFR subtypes ex19del and L8585R, and small
differences were observed (Table 6).
3.3.2 | Safety and tolerability of ASP8273 300 mg
At the 300 mg dose, TEAEs occurring in ≥20% of patients were diar-
rhea (66%; n = 50), nausea (41%; n = 31), increased ALT (36%;
n = 27), vomiting and decreased appetite (34%; n = 26 each),
hyponatremia (33%; n = 25), constipation (26%; n = 20), peripheral
sensory neuropathy (25%; n = 19), and increased AST (24%; n = 18).
Fatal TEAEs occurred in two patients: one patient experienced grade
5 TEAEs, pneumonia and dyspnea, 88 days after initiating treatment
with 300 mg ASP8273; the other patient experienced grade 5 TEAEs
leptomeningeal carcinomatosis, cough, and dyspnea, 108 days after
initiating treatment. None of these fatal TEAEs was considered
related to ASP8273. Serious drug‐related TEAEs were reported in
F IGURE 3 Pharmacokinetic profile of ASP8273 in Phase I (dose escalation) and Phase II (dose expansion). A, Single‐dose ASP8273 plasma
concentration (phase I). B, Repeat‐dose ASP8273 plasma concentration (phase I). C, Single‐dose ASP8273 plasma concentration (phase II). D,
Repeat‐dose ASP8273 plasma concentration (phase II)
TABLE 3 Best overall response rate (ORR) across all doses (local review) among patients with non‐small‐cell lung cancer treated with
ASP8273
25‐100 mg (n = 11) 200 mg (n = 10) 300 mg (n = 10) 400 mg (n = 10) 600 mg (n = 4) Total (N = 45)
CR, n (%) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0)
PR, n (%) 2 (18) 5 (50) 5 (50) 7 (70) 3 (75) 22 (49)
SD, n (%) 8 (73) 4 (40) 3 (30) 3 (30) 0 (0) 18 (40)
ORR, % (95% CIa) 18 (2.28, 51.8) 50 (18.7, 81.3) 50 (18.7, 81.3) 70 (34.8, 93.3) 75 (19.4, 99.4) 49 (33.7, 64.2)
DCR, % (95% CIa) 90 (58.7, 99.8) 90 (55.5, 99.7) 80 (44.4, 97.5) 100 (69.2, 100) 75 (19.4, 99.4) 89 (75.9, 96.3)
aBased on exact binomial confidence interval (CI; Clopper–Pearson).
CR, complete response; DCR, disease control rate (CR + PR + SD); PR, partial response; SD, stable disease.
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21% of patients (16/76); the most common (≥2 patients) were
hyponatremia (7%; n = 5/76), increased ALT, and decreased appetite
(3%; n = 2/76 each). Treatment‐emergent AEs leading to permanent
discontinuation were reported by 6/76 patients; these were
infectious pleural effusion, pneumonia, pyelonephritis, sepsis,
hyponatremia, metastases to meninges, and organizing pneumonia.
In phase II, TRAEs were reported by 93% of patients (n = 71);
the most frequently reported were diarrhea (57%; n = 43), hypona-
tremia and increased ALT (29%; n = 22 each), and vomiting (28%;
n = 21). Most TRAEs were mild in severity, however, 15 reports of
hyponatremia were grade ≥3 (Table 7).
4 | DISCUSSION
Treatment of patients with NSCLC remains a challenge because
many of these patients acquire drug resistance with a secondary
mutation (T790M) following treatment with EGFR TKIs. In this
phase I/II study of patients with EGFR‐mutant lung cancer in Japan,
Korea, and Taiwan, AEs during both phases were similar to those
observed with other drugs in this class,10 and 63 patients achieved
a clinical response (based on independent central review) after
treatment with ASP8273 for both stages of phase II combined
(ORR 42.9%; 95% CI, 30.5, 56.0). These findings provide further
insight into achieving the optimal antitumor effects of third‐genera-
tion EGFR TKIs for NSCLC.
ASP8273 given orally daily was generally well tolerated and AEs
were manageable in patients with NSCLC. During phase I of the
study (dose‐escalation), DLTs were experienced by 20% of patients
(9/45), and ASP8273 300 mg was identified as the RP2D and
400 mg as the MTD. During phase II (dose‐expansion), 93.4% of
patients reported drug‐related AEs, the most common of which was
diarrhea (57%; n = 43/76). These events were anticipated from other
EGFR TKIs in patients with NSCLC.10 During phase I, one patient
who was treated with 600 mg ASP8273 experienced interstitial lung
disease of grade 2 or lower. Hyponatremia and peripheral sensory
neuropathy occurred more frequently with ASP8273 compared with
other drugs in the class, which was consistent with findings from a
F IGURE 4 Maximum percent change
from baseline in tumor size in patients
with non‐small‐cell lung cancer treated
with ASP8273 (phase I, local review)
TABLE 4 Best overall response rate (ORR) to ASP8273 among
patients with non‐small‐cell lung cancer by epidermal growth factor







CR, n (%) 0 (0) 0 (0) 0 (0)
PR, n (%) 12 (52) 2 (33) 8 (50)
SD, n (%) 10 (44) 1 (17) 7 (44)
ORR, % (95%
CI)a
52 (30.6, 73.2) 33 (4.3, 77.7) 50 (24.7, 75.3)
DCR, % (95%
CI)a
96 (78.1, 99.9) 50 (11.8, 88.2) 94 (69.8, 99.8)
Data presented as n (%).
aBased on exact binomial confidence interval (CI; Clopper‐Pearson).
CR, complete response; DCR, disease control rate; PR, partial response;
SD, stable disease.
TABLE 5 Best overall response rate (ORR) at week 24 (central
review) among patients with non‐small‐cell lung cancer treated with
ASP8273, phase II (full analysis set)
300 mg (N = 76)
CR, n (%) 0
PR, n (%) 32 (42)
SD, n (%) 29 (38)
ORR, % (95% CI)a 42 (30.9, 54.0)
DCR, % (95% CI)a 80 (69.5, 88.5)
Data presented as n (%).
aBased on exact binomial confidence interval (CI, Clopper‐Pearson).
CR, complete response; DCR, disease control rate; PR, partial response;
SD, stable disease.
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phase I study of patients with EGFR‐mutation‐positive NSCLC
undertaken in the USA (NCT02113813). Hyponatremia is a serious
adverse event that is common among patients with metastatic lung
cancer. In a clinical trial with EGFR TKI gefitinib in patients with
advanced NSCLC, a total of 3 of 40 patients (8%) experienced grade
3 hyponatremia. During phase II of this study, hyponatremia grade
≥3 occurred in 20% of patients treated with ASP8273. Although this
rate is higher than targeted lung cancer agents, in this study, treat-
ment‐emergent hyponatremia was not considered to be cause for
discontinuation of the clinical trial. Instances of treatment‐related
peripheral sensory neuropathy (occurring among 18/76, 24% of
patients) were mild in severity (grade 1 or 2).
ASP8273 showed linear pharmacokinetics and dose proportional-
ity over the dose range of 100‐400 mg. Oral absorption of ASP8273
occurred rapidly; maximum concentrations were achieved within 1
to 6 hours after a single dose and at steady state. Steady‐state
ASP8723 was achieved by day 8 after once‐daily dosing. Median ter-
minal elimination half‐life of ASP8273 ranged from approximately 11
to 14 hours across the 50 to 600 mg dose range.
Tumor imaging data suggested that responses occurred in
patients in all dose groups above 100 mg; additionally, when antitu-
mor activity was assessed by T790M status, ORRs, PFS, and DCRs
with ASP8273 (25‐600 mg) were higher in patients with a known
T790M mutation than patients with no T790M mutation. However,
due to the small number of patients in these subgroups, these data
should be interpreted with caution.
F IGURE 5 Maximum percent change
from baseline in tumor size in patients
with epidermal growth factor receptor
T790M mutation‐positive non‐small‐cell
lung cancer (phase II, central assessment)
TABLE 6 Overall response rate (ORR) and median duration of progression‐free survival (PFS) at week 24 (phase II) among patients with
non‐small‐cell lung cancer treated with ASP8273, by exon 19 deletion (ex19del) and L858R
Ex19del+ (n = 49) Ex19del− (n = 27) L858R+ (n = 23) L858R− (n = 53)
PFS months (95% CI) 8.1 (5.6, upper bound
not reached)
5.6 (3.0, upper bound
not reached)
5.6 (2.6, upper bound
not reached)
8.1 (5.7, upper bound
not reached)
ORR (95% CI) 47% (32.5, 61.7) 33% (16.5, 54.0) 35% (16.4, 57.3) 45% (31.6, 59.6)
CI, confidence interval; –, upper bound not reached.
TABLE 7 Incidence of overall treatment‐related adverse events
(TRAEs) and grade ≥3 TRAEs occurring in ≥10% of patients with
non‐small‐cell lung cancer treated with ASP8273 (phase II) at initial
dose level (safety analysis set)





Overall 71 (93) 29 (38)
Constipation 9 (12) 0 (0)
Diarrhea 43 (57) 0 (0)
Nausea 20 (26) 0 (0)
Vomiting 21 (28) 0 (0)
Malaise 10 (13) 0 (0)
Alanine aminotransferase increased 22 (29) 3 (4)
Aspartate aminotransferase increased 13 (17) 2 (3)
Platelet count decreased 13 (17) 0 (0)
Decreased appetite 12 (16) 3 (4)
Hyponatremia 22 (29) 15 (20)
Dysgeusia 9 (12) 0 (0)
Hypoesthesia 8 (11) 0 (0)
Peripheral sensory neuropathy 18 (24) 0 (0)
TRAEs of special interest
Rash 5 (7) 0 (0)
QTc prolongation 5 (7) 0 (0)
Interstitial lung disease 0 (0) 0 (0)
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In summary, the phase I portion of this study identified the
RP2D and MTD of ASP8273 as 300 and 400 mg, respectively, when
given orally to patients with clinical stage IV NSCLC. Additionally,
we observed during phase II that ASP8273 has a manageable toxic-
ity profile and patients achieved a response rate (CR + PR) of 43%,
suggesting ASP8273 has potential antitumor effects.
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